Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Lurasidone Hydrochloride

October 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Lurasidone hydrochloride

Dosage Form: Tablet

Route: Oral

Strengths: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 40 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: (1) Study population should consist of healthy subjects at least 18 years of age with no clinically relevant abnormalities identified by a detailed medical history, full physical examination including vital signs (blood pressure, pulse rate, respiratory rate and temperature), 12-lead electrocardiogram (ECG), and clinical laboratory tests. Females should not be pregnant or lactating, and, if applicable, should practice abstention or contraception during the study. (2) To minimize risks, based on the current knowledge, subjects with any of the following conditions should be excluded from the bioequivalence study:
   a. A history or diagnosis of any cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunologic, hematologic or psychiatric disorders.
   b. Subjects who are on strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.).

c. Blood pressure, heart rate, and body temperature should be monitored during the study and immediate medical care provided for any significant abnormalities.

Analyte to measure: Lurasidone in plasma

Bioequivalence based on (90% CI): Lurasidone

Waiver request of in vivo testing: 20 mg, 60 mg, 80 mg, and 120 mg based on (i) acceptable bioequivalence study on the 40 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution. Conduct comparative dissolution testing on 12 dosage units for each of all strengths of the test product and reference listed drug (RLD).[1] Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended December 2014; Revised October 2024

Unique Agency Identifier: PSG_200603

[1] If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions.*